These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 15807842)

  • 21. New therapeutic approaches for rheumatoid arthritis.
    Abdelaty EM; Schumacher HR
    Int J Clin Pract; 1999; 53(7):535-9. PubMed ID: 10692740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
    De Vita S; Quartuccio L
    Autoimmun Rev; 2006 Aug; 5(7):443-8. PubMed ID: 16920570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheumatoid arthritis: an overview of new and emerging therapies.
    Doan T; Massarotti E
    J Clin Pharmacol; 2005 Jul; 45(7):751-62. PubMed ID: 15951465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted therapy in rheumatoid arthritis.
    Köller MD
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the role of rituximab in the treatment of rheumatoid arthritis?
    Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an update.
    Giasuddin AS; Hoque ME; Ahmed ZU
    Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):88-94. PubMed ID: 17549869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unmet needs in rheumatoid arthritis.
    Moreland L
    Arthritis Res Ther; 2005; 7 Suppl 3(Suppl 3):S2-8. PubMed ID: 15960819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new era in rheumatoid arthritis treatment.
    Costello JC; Halverson PB
    WMJ; 2003; 102(7):29-33. PubMed ID: 14711021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V; Kavanaugh AF
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
    Chatzidionysiou K; van Vollenhoven RF
    J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
    Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
    J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.